Negative free cash flow remains a structural concern, with quarterly outflows reaching $2.0 million in 2025Q2, necessitating ongoing reliance on external financing.
| Cash from Operations | -5.55M | -2.95M | -446.92K | -599.57K | -284.02K |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | -7461.78% | -559.3% | 25.46% | -111.1% | - |
| Net Income | -11.29M | -6.15M | -707.46K | -598.59K | -1.11M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.54M | 2.65M | 0 | 1.4K | 821.15K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.78M | 403.71K | 0 | 0 | 0 |
| Working Capital Changes | -587.04K | 150.57K | 260.54K | -2.38K | 3.85K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -258.5K | -187.57K | 104K | -7.12K | -12.9K |
| Cash from Investing | 0 | -123.5K | 23.85K | -125.41K | 0 |
| Capital Expenditures | 0 | -123.5K | -13.89K | -125.41K | 0 |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 37.74K | 0 | 0 |
| Cash from Financing | 12.85M | 3.13M | 350K | 500K | 250K |
| Debt Issued (Net) | 496.82K | 2.18M | 0 | 0 | 0 |
| Equity Issued (Net) | -114.7K | 175K | 0 | 750K | 250K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -120K | 0 | 0 | 0 |
| Other Financing | 12.47M | 778.94K | 350K | -250K | 0 |
| Net Change in Cash | 7.3M | 60.93K | -73.06K | -224.98K | -34.02K |
| Free Cash Flow | -5.55M | -3.07M | -460.8K | -724.98K | -284.02K |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | -145.46% | -566.23% | 36.44% | -155.26% | - |
| FCF per Share | -0.09 | -0.16 | -0.02 | -0.04 | -0.01 |
| FCF Conversion (FCF/Net Income) | 0.49x | 0.48x | 0.63x | 1.00x | 0.26x |
| Interest Paid | 79.15K | 2.46K | 78.5K | 19.62K | 0 |
| Taxes Paid | 551.59K | 551.59K | 0 | 0 | 0 |
Imminent liquidity and dilution
According to recent financial filings, KLTOW's operating cash flow consistently trails net losses, with the OCF/NI ratio fluctuating between 0.36 and 0.70 in recent quarters, suggesting that non-cash expenses and working capital adjustments are masking the true magnitude of the company's ongoing cash consumption.
The persistent gap between net income and operating cash flow indicates that the company's accounting losses do not fully capture the cash-based operational requirements of its preclinical research. Investors should monitor this divergence, as it suggests that the firm's reliance on non-cash items to manage the bottom line provides little relief from the underlying cash burn.
As reported in quarterly statements, KLTOW has maintained a negative free cash flow trajectory, with quarterly outflows reaching $2.0 million in 2025Q2, highlighting a structural inability to generate internal funding while the company remains entirely dependent on external capital to sustain its research and development pipeline.
The absence of positive free cash flow is characteristic of a pre-revenue biotech, yet the scale of the burn relative to the reported cash balance of $63,741 appears unsustainable. This trajectory implies that the company is rapidly approaching a critical juncture where operational continuity will depend entirely on the success of future dilutive financing rounds.
Based on the provided cash flow data, working capital changes have been highly erratic, swinging from a $464.9K outflow in 2025Q1 to a $26.6K inflow in 2025Q3, which may indicate inconsistent management of payables or timing differences in the settlement of research-related liabilities.
Such volatility in working capital often reflects the precarious nature of a firm operating with minimal liquidity. The inability to stabilize these flows suggests that the company may be managing its cash on a project-by-project basis, which warrants further investigation into the maturity of its outstanding accounts payable.
Financial disclosures reveal that stock-based compensation, which peaked at $2.0 million in 2024Q3, has been utilized as a primary mechanism to preserve cash, effectively shifting the cost of talent acquisition from the cash flow statement to the equity base of the company.
While this strategy preserves limited liquid assets, it creates a significant overhang of potential dilution that investors must account for when valuing the firm. The reliance on equity-based incentives appears to be a necessary survival tactic rather than a standard compensation practice, given the company's extremely constrained cash position.
Quick answers to the most common questions about buying KLTOW stock.
Klotho Neurosciences, Inc. (KLTOW) generated $-2.9M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Klotho Neurosciences, Inc. (KLTOW) reported negative free cash flow of $3.1M in 2024, indicating capital requirements exceeded cash from operations.
Klotho Neurosciences, Inc. (KLTOW) spent $0.1M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2024, Klotho Neurosciences, Inc. (KLTOW) spent $0.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.